Zafrens raises $6.0M Series A (United States, Nov 2026)
Reach the investors backing rounds like this
Backed by Trill Impact, imec.xpand · verified emails and LinkedIn on Datapile
Zafrens adds $6M to Series A as Trill Impact makes first TechBio bet - Dealroom
Zafrens is a San Diego-based drug discovery company that has developed the Z-Screen platform, combining microfluidics, longitudinal cell imaging, and sequencing to rapidly test large numbers of potential medicines. The company aims to validate biological hypotheses faster than traditional methods by linking molecular data to cell function at high throughput. This funding will advance its internal drug pipeline and expand its screening platform.
Zafrens adds $6M to Series A as Trill Impact makes first TechBio bet Dealroom
| Nov 02, 2026 | Activ Surgical | $45.0M | Series B | United States |
| Nov 02, 2026 | Phoenix fintech startup | $12.0M | — | United States |
| Nov 02, 2026 | Northwood Space | $375.0M | Series C | United States |
| Nov 02, 2026 | Idealab.ai | $30.0M | — | United States |
23,411 investors back startups in United States
You just read who funded Zafrens. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.